| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA5163566 | F | Ex vivo receptor occupancy at V2R in isolated perfused Sprague-Dawley rat kidney assessed as dissociation half life at 0.1 uM incubated for 30 mins by LC-MS analysis | Rattus norvegicus | 2 | tissue-based format | Scientific Literature | ||
| 2. | ALA5163568 | F | Suppression of renal cyst development in embryonic kidney of 8-Br-cAMP induced C57BL/6 mouse mouse model of autosomal dominant polycystic kidney disease assessed as residence time dependent measured after 8 days | Mus musculus | 10 | organism-based format | Scientific Literature | ||
| 3. | ALA5163569 | B | Displacement of conivaptan-red from SNAP-tagged V2 receptor (unknown origin) expressed in HEK293 cells assessed as inhibition constant measured after 2 hrs by HTRF assay | Homo sapiens | 10 | cell-based format | Scientific Literature | ||
| 4. | ALA5163570 | B | Inhibition of conivaptan-red binding to SNAP-tagged V2 receptor (unknown origin) expressed in HEK293 cells assessed as binding constant (Kon) measured after 2 hrs by HTRF competitive binding assay | Homo sapiens | 10 | cell-based format | Scientific Literature | ||
| 5. | ALA5163571 | B | Inhibition of conivaptan-red binding to SNAP-tagged V2 receptor (unknown origin) expressed in HEK293 cells assessed as binding constant (Koff) measured after 2 hrs by HTRF competitive binding assay | Homo sapiens | 10 | cell-based format | Scientific Literature | ||
| 6. | ALA5163572 | B | Inhibition of conivaptan-red binding to SNAP-tagged V2 receptor (unknown origin) expressed in HEK293 cells assessed as residence time (1/koff) measured after 2 hrs by HTRF competitive binding assay | Homo sapiens | 10 | cell-based format | Scientific Literature | ||
| 7. | ALA5163573 | F | Antagonist activity at human V2 receptor expressed in CHO cells assessed as reduction in vasopressin induced cAMP production preincubated for 30 mins followed by vasopressin stimulation and measured after 30 mins | Homo sapiens | 3 | cell-based format | Scientific Literature | ||
| 8. | ALA5163574 | F | Insurmountable antagonist activity at human V2 receptor expressed in CHO cells assessed as decrease in maximal response preincubated for 30 mins followed by vasopressin stimulation and measured after 30 mins | Homo sapiens | 2 | cell-based format | Scientific Literature | ||
| 9. | ALA5163575 | F | Antagonist activity at human V2 receptor expressed in CHO cells assessed as recovery of cAMP production preincubated for 30 mins followed by compound washout and subsequent vasopressin stimulation for 30 mins and measured after 1 hr | Homo sapiens | 3 | cell-based format | Scientific Literature | ||
| 10. | ALA5163576 | F | Antagonist activity at human V2 receptor expressed in CHO cells assessed as assessed as target occupancy preincubated for 30 mins followed by vasopressin stimulation for 30 mins | Homo sapiens | 2 | cell-based format | Scientific Literature | ||
| 11. | ALA5163578 | F | Suppression of renal cyst development in embryonic kidney of 8-Br-cAMP induced C57BL/6 mouse mouse model of autosomal dominant polycystic kidney disease measured after 8 days | Mus musculus | 10 | organism-based format | Scientific Literature | ||
| 12. | ALA5163579 | F | Invivo antagonist activity at V2R in Pkd1 knockout mouse model of autosomal dominant polycystic kidney disease assessed as reduction in kidney size at 2 mg/kg, sc administered once daily treatment started from postnatal day 6 to 12 days | Mus musculus | 10 | organism-based format | Scientific Literature | ||
| 13. | ALA5163580 | T | Toxicity in wild type mouse assessed as effect on kidney size | Mus musculus | 10 | tissue-based format | Scientific Literature | ||
| 14. | ALA5163581 | T | Toxicity in wild type mouse assessed as effect on body weight | Mus musculus | 10 | assay format | Scientific Literature | ||
| 15. | ALA5163582 | F | Invivo antagonist activity at V2R in Pkd1 knockout mouse model of autosomal dominant polycystic kidney disease assessed as reduction of renal cyst formation 2 mg/kg, sc administered once daily treatment started from postnatal day 6 to 12 days by hematoxylin and eosin staining based assay | Mus musculus | 3 | organism-based format | Scientific Literature | ||
| 16. | ALA5163583 | A | Elimination rate constant in C57BL/6 mouse at 2 mg/kg, sc by LC-MS analysis | Mus musculus | 10 | organism-based format | Scientific Literature | ||
| 17. | ALA5163584 | A | Half life in C57BL/6 mouse at 2 mg/kg, sc by LC-MS analysis | Mus musculus | 10 | organism-based format | Scientific Literature | ||
| 18. | ALA5163585 | A | Tmax in C57BL/6 mouse at 2 mg/kg, sc by LC-MS analysis | Mus musculus | 10 | organism-based format | Scientific Literature | ||
| 19. | ALA5163586 | A | Cmax in C57BL/6 mouse at 2 mg/kg, sc by LC-MS analysis | Mus musculus | 10 | organism-based format | Scientific Literature | ||
| 20. | ALA5163587 | A | AUC (0 to t) in C57BL/6 mouse at 2 mg/kg, sc by LC-MS analysis | Mus musculus | 10 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!